Ads
related to: new research on schizophrenia treatment plan goals and objectives for depression
Search results
Results from the WOW.Com Content Network
A new first-in-class antipsychotic that targets multiple neurotransmitter systems called lumateperone (ITI-007), was trialed and approved by the FDA in December 2019 for the treatment of schizophrenia in adults. [24] [26] [27] Lumateperone is a small molecule agent that shows improved safety, and tolerance.
More than 40 percent of all people with schizophrenia end up in supervised group housing, nursing homes or hospitals. Another 6 percent end up in jail, usually for misdemeanors or petty crimes, while an equal proportion end up on the streets. Among researchers, schizophrenia has long been known as the “graveyard of psychiatric research.”
The Brain & Behavior Research Foundation (BBRF) is a nonprofit 501(c)(3) organization that funds mental health research. It was originally called the National Alliance for Research on Schizophrenia & Depression, or NARSAD. It received its nonprofit ruling in 1981. [1] [2]
Empirical support for cognitive remediation in traumatic brain injury and schizophrenia is documented by published randomized controlled trials and meta-analyses. [1] [2] [3] Effects on cognitive skill performance in schizophrenia are durable for months after the therapies are withdrawn, particularly in terms of executive functioning, working memory, and verbal memory.
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in more than 30 years. Cobenfy, manufactured by Bristol Myers Squibb ...
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, according to a press release. “This drug takes the first new approach to ...
It is an official journal of the Schizophrenia International Research Society and was established in 1988. The editor-in-chief is Matcheri Keshavan and the former editors are Henry Nasrallah (University of Cincinnati) and Lynn DeLisi (Harvard Medical School). According to Schizophrenia Research 's original mission statement, the journal is aimed at
However, the Soteria Research Project was also the subject of much controversy. [5] One of the main critiques was that the project was withholding evidence-based treatment as it was based on invalid anti-medication and anti-disease models, which went against the widely accepted biopsychosocial model of disease.
Ads
related to: new research on schizophrenia treatment plan goals and objectives for depression